Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
10 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 36(6); December 2004
Prev issue Next issue
Editorial
Preoperative Concurrent Chemoradiotherapy with Oral Fluoropyrimidine in Locally Advanced Rectal Cancer: How Good Is Good Enough?
Hyun Cheol Chung
Cancer Res Treat. 2004;36(6):341-342.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.341
PDFPubReaderePub
  • 6,786 View
  • 57 Download
Close layer
Review Article
HIF-1α: a Valid Therapeutic Target for Tumor Therapy
Soon-Sun Hong, Hyunseung Lee, Kyu-Won Kim
Cancer Res Treat. 2004;36(6):343-353.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.343
AbstractAbstract PDFPubReaderePub

Hypoxia plays a major role in the induction of angiogenesis during tumor development. One mechanism by which tumor cells respond to a reduced oxygen level is via the activation of hypoxia-inducible factor-1 (HIF-1). HIF-1 is an oxygen-dependent transcriptional activator that plays crucial roles in the angiogenesis of tumors and mammalian development. HIF-1 consists of a constitutively expressed HIF-1β subunit and the highly regulated HIF-1α subunits. The stability and activity of HIF-1α are regulated by various post-translational modifications, hydroxylation, acetylation, phosphorylation and sumoyaltion. Therefore, HIF-1α interacts with several protein factors including PHD, pVHL, ARD-1, SUMO and p300/CBP. Under normoxia, the HIF-1α subunit is rapidly degraded via the von Hippel-Lindau tumor suppressor gene product (pVHL)-mediated ubiquitin/proteasome pathway. The association of pVHL and HIF-1α under normoxic conditions is triggered by the hydroxylation of prolines and the acetylation of lysine within a polypeptide segment known as the oxygen-dependent degradation (ODD) domain. On the contrary, under the hypoxia condition, the HIF-1α subunit becomes stable and interacts with coactivators such as p300/CBP to modulate its transcriptional activity. Under hypoxic conditions, HIF-1 eventually acts as a master regulator of numerous hypoxia-inducible genes. The target genes of HIF-1 are especially related to angiogenesis, cell proliferation and survival, and to glucose and iron metabolism. Moreover, it was reported that the activation of HIF-1α is closely associated with a variety of tumors and oncogenic pathways. Hence, the blocking of HIF-1α itself or the blocking of HIF-1α interacting proteins inhibits tumor growth. Based on these findings, HIF-1 can be a prime target for anticancer therapies. Therefore, this review summarizes the molecular mechanism of HIF-1α stability, the biological functions of HIF-1 and its potential applications for cancer therapies.

Citations

Citations to this article as recorded by  
  • Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application
    Liang Zhao, Junchen Guo, Shasha Xu, Meiqi Duan, Baiming Liu, He Zhao, Yihan Wang, Haiyang liu, Zhi Yang, Hexue Yuan, Xiaodi Jiang, Xiaofeng Jiang
    Journal of Advanced Research.2025; 70: 159.     CrossRef
  • Synthesis and discovery of simplified pleurotin analogs bearing tricyclic core as novel thioredoxin reductase inhibitors
    Bin Huang, Zhongren Xu, Dezhong Liao, Yuxia Zhang, Mengze Ruan, Zhiyue Fan, Wukun Liu, Ya-Qiu Long
    European Journal of Medicinal Chemistry.2025; 285: 117242.     CrossRef
  • Living Microalgae‐Based Magnetic Microrobots for Calcium Overload and Photodynamic Synergetic Cancer Therapy
    Shuai Jiang, Bo Hao, Xin Song, Yihang Jiang, Junjia Guo, Yuqiong Wang, Qinglong Wang, Xin Wang, Tiantian Xu, Xinyu Wu, Kai Fung Chan, Philip Wai Yan Chiu, Li Zhang
    Advanced Healthcare Materials.2025;[Epub]     CrossRef
  • A comprehensive review on therapeutic potentials of photobiomodulation for neurodegenerative disorders
    Pooja Ramakrishnan, Aradhana Joshi, Mohamed Fazil, Pankaj Yadav
    Life Sciences.2024; 336: 122334.     CrossRef
  • Novel Benzochromenes: Design, Synthesis, Cytotoxicity, Molecular Docking and Mechanistic Investigations
    Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed A Al-Karmalawy, Ebtehal M Husseiny
    Future Medicinal Chemistry.2024; 16(2): 105.     CrossRef
  • Role of natural secondary metabolites as HIF-1 inhibitors in cancer therapy
    Prem Shankar Mishra, Rakhi Mishra, Vaishali Manikrao Patil, Samiksha Dewangan
    Medicinal Chemistry Research.2024; 33(5): 721.     CrossRef
  • SIMULATED AEROMEDICAL EVACUATION EXACERBATES ACUTE LUNG INJURY VIA HYPOXIA-INDUCIBLE FACTOR-1α-MEDIATED BNIP3/NIX-DEPENDENT MITOPHAGY
    Chunli Yin, Xinyang Liu, Yujie Ma, Zibo Tang, Wenmin Guo, Bingbing Sun, Jingmei He
    Shock.2024;[Epub]     CrossRef
  • Inferring upstream regulatory genes of FOXP3 in human regulatory T cells from time-series transcriptomic data
    Stefano Magni, Rucha Sawlekar, Christophe M. Capelle, Vera Tslaf, Alexandre Baron, Ni Zeng, Laurent Mombaerts, Zuogong Yue, Ye Yuan, Feng Q. Hefeng, Jorge Gonçalves
    npj Systems Biology and Applications.2024;[Epub]     CrossRef
  • Stilbenoid derivatives as potent inhibitors of HIF-1α-centric cancer metabolism under hypoxia
    Tae-Hee Han, Joohan Lee, Dipesh S. Harmalkar, Hyeseul Kang, Guanghai Jin, Min Kyung Park, Minkyoung Kim, Hyun-A Yang, Jinsu Kim, Su Jeong Kwon, Tae-Su Han, Yongseok Choi, Misun Won, Hyun Seung Ban, Kyeong Lee
    Biomedicine & Pharmacotherapy.2024; 176: 116838.     CrossRef
  • Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy
    Delong Han, Zeyu Li, Lingjie Luo, Hezhong Jiang
    Biology.2024; 13(8): 577.     CrossRef
  • The Effects of Normobaric Hypoxia on the Acute Physiological Responses to Resistance Training: A Narrative Review
    Giselle L. Allsopp, Florian A. Britto, Craig R. Wright, Louise Deldicque
    Journal of Strength & Conditioning Research.2024;[Epub]     CrossRef
  • Physiological hypoxia promotes cancer cell migration and attenuates angiogenesis in co-culture using a microfluidic device
    Satoshi Aratake, Kenichi Funamoto
    Microfluidics and Nanofluidics.2024;[Epub]     CrossRef
  • Design, synthesis, molecular dynamics and gene silencing studies of novel therapeutic HIF-1α siRNAs in hypoxic cancer cells
    Jyoti Singh, Sneha Yadav, Archana Bharti Sonkar, Anurag Kumar, Neeraj Kumar Shrivastava, Rohit Kumar, Dharmendra Kumar, Mohd Nazam Ansari, Abdulaziz S. Saeedan, Gaurav Kaithwas
    International Journal of Biological Macromolecules.2024; 282: 136943.     CrossRef
  • Concise Asymmetric Total Syntheses of (+)-Dihydropleurotinic Acid and (−)-Pleurotin, Enabling Rapid Late-Stage Diversification
    Bin Huang, Jing Pang, Nan Cao, Ya-Shuang Dai, Ya-Qiu Long
    JACS Au.2024; 4(11): 4206.     CrossRef
  • The Physiological Functions and Therapeutic Potential of Hypoxia-Inducible Factor-1α in Vascular Calcification
    Zhenghong Zhang, Defan Wang, Renfeng Xu, Xiang Li, Zhengchao Wang, Yang Zhang
    Biomolecules.2024; 14(12): 1592.     CrossRef
  • Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence
    Yarden Zohar, Nicola J. Mabjeesh
    Expert Opinion on Therapeutic Targets.2023; 27(8): 715.     CrossRef
  • Transcriptome Analysis on Hepatopancreas Reveals the Metabolic Dysregulation Caused by Vibrio parahaemolyticus Infection in Litopenaeus vannamei
    Miao Miao, Shihao Li, Yuan Liu, Yang Yu, Fuhua Li
    Biology.2023; 12(3): 417.     CrossRef
  • Determination of HIF-1α degradation pathways via modulation of the propionyl mark
    Kwanyoung Jeong, Jinmi Choi, Ahrum Choi, Joohee Shim, Young Ah Kim, Changseok Oh, Hong-Duk Youn, Eun-Jung Cho
    BMB Reports.2023; 56(4): 252.     CrossRef
  • Baf155 regulates skeletal muscle metabolism via HIF-1a signaling
    Jong-Seol Kang, Dongha Kim, Joonwoo Rhee, Ji-Yun Seo, Inkuk Park, Ji-Hoon Kim, Daewon Lee, WonUk Lee, Ye Lynne Kim, Kyusang Yoo, Sunghwan Bae, Jongkyeong Chung, Rho Hyun Seong, Young-Yun Kong, Simon M. Hughes
    PLOS Biology.2023; 21(7): e3002192.     CrossRef
  • Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease
    Christopher Bailey, Yuanyi Wei, Jinsong Yan, Dan Huang, Peng Zhang, Chong Qi, Christopher Lazarski, JuanJuan Su, Fei Tang, Chun-shu Wong, Pan Zheng, Yan Liu, Yang Liu, Yin Wang
    Cell Reports Medicine.2023; 4(11): 101236.     CrossRef
  • Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [64Cu][Cu(ATSM)] PET and proteomic studies
    Jade Fantin, Jérôme Toutain, Elodie A. Pérès, Benoit Bernay, Sarina Maya Mehani, Charly Helaine, Mickael Bourgeois, Carole Brunaud, Laurent Chazalviel, Julien Pontin, Aurélien Corroyer-Dulmont, Samuel Valable, Michel Cherel, Myriam Bernaudin
    EJNMMI Research.2023;[Epub]     CrossRef
  • Exploring mRNA Translation Strategies for Hypoxia Adaptation Across Distantly Related Metazoans
    Manfei Liang, Qingyou Zhao, Yixiang Song, Jianchao Chen
    Epigenomics.2023; 15(20): 1069.     CrossRef
  • Novel thioether linked 4-hydroxycoumarin derivatives: Synthesis, characterization, in vitro pharmacological investigation and molecular docking studies
    B. Manjunatha, Yadav D. Bodke, H.M. Kumaraswamy, P. Meghana, O. Nagaraja, G.C. Anjan kumar
    Journal of Molecular Structure.2022; 1249: 131642.     CrossRef
  • A Concise Synthesis of Pleurotin Enabled by a Nontraditional C–H Epimerization
    John F. Hoskin, Erik J. Sorensen
    Journal of the American Chemical Society.2022; 144(31): 14042.     CrossRef
  • Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells
    Hsing-Hua Chao, Jun-Liang Luo, Ming-Hsuan Hsu, Li-Han Chen, Tzu-Pin Lu, Mong-Hsun Tsai, Eric Y. Chuang, Li-Ling Chuang, Liang-Chuan Lai
    Cell Death & Disease.2022;[Epub]     CrossRef
  • A dynamic fluorescence probed glycolysis suppression process in HeLa cells treated with trichostatin A
    Fengqiu Zhang, Changsheng Shao, Yahui Wu, Wei Zhao, Xumiao Jing, Cao Fang, Qing Huang
    The Analyst.2022; 147(22): 5082.     CrossRef
  • Polystyrene-Based Slippery Surfaces Enable the Generation and Easy Retrieval of Tumor Spheroids
    Priyanka Pulugu, Neha Arya, Prasoon Kumar, Akshay Srivastava
    ACS Applied Bio Materials.2022; 5(12): 5582.     CrossRef
  • Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
    Shereen El Shorbagy, Fouad abuTaleb, Hany A. Labib, Huda Ebian, Ola A. Harb, Mona Saeed Mohammed, Hanaa A. Rashied, Khaled A. Elbana, Rasha Haggag
    Journal of Gastrointestinal Cancer.2021; 52(1): 269.     CrossRef
  • Adenylate Kinase 4 Promotes Inflammatory Gene Expression via Hif1α and AMPK in Macrophages
    Wei-Yao Chin, Chi-Ying He, Tsun Wai Chow, Qi-You Yu, Liang-Chuan Lai, Shi-Chuen Miaw
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Stabilization of Hypoxia-Inducible Factor Promotes Antimicrobial Activity of Human Macrophages Against Mycobacterium tuberculosis
    Sebastian F. Zenk, Sebastian Hauck, Daniel Mayer, Mark Grieshober, Steffen Stenger
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas
    Shang-Pen Huang, Chien-Hsiu Li, Wei-Min Chang, Yuan-Feng Lin
    Biology.2021; 10(8): 701.     CrossRef
  • The cytotoxic effect of Baeckea frustescens extracts in eliminating hypoxic breast cancer cells
    S. H. Shahruzaman, F. Z. Yusof, S. Maniam, S. Fakurazi, S. Maniam
    BMC Complementary Medicine and Therapies.2021;[Epub]     CrossRef
  • A highly annotated database of genes associated with platinum resistance in cancer
    Dongqing Huang, Sara R. Savage, Anna P. Calinawan, Chenwei Lin, Bing Zhang, Pei Wang, Timothy K. Starr, Michael J. Birrer, Amanda G. Paulovich
    Oncogene.2021; 40(46): 6395.     CrossRef
  • Lung Adenocarcinoma Transcriptomic Analysis Predicts Adenylate Kinase Signatures Contributing to Tumor Progression and Negative Patient Prognosis
    Jonathan A. Chacon-Barahona, Ivan A. Salladay-Perez, Nathan James Lanning
    Metabolites.2021; 11(12): 859.     CrossRef
  • Clinicopathological significance and angiogenic role of the constitutive phosphorylation of the FOXO1 transcription factor in colorectal cancer
    Young San Ko, Nae Yu Kim, Jung-Soo Pyo
    Pathology - Research and Practice.2020; 216(11): 153150.     CrossRef
  • Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
    Yue Zhao, Fei Feng, Qing-Hong Guo, Yu-Ping Wang, Rui Zhao
    World Journal of Gastroenterology.2020; 26(34): 5074.     CrossRef
  • Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan
    Carla Almendáriz-Palacios, Darrell D. Mousseau, Christopher H. Eskiw, Zoe E. Gillespie
    International Journal of Molecular Sciences.2020; 21(23): 9220.     CrossRef
  • Long Noncoding RNA Expression Profiling Reveals Upregulation of Uroplakin 1A and Uroplakin 1A Antisense RNA 1 under Hypoxic Conditions in Lung Cancer Cells
    Yuree Byun, Young-Chul Choi, Yongsu Jeong, Jaeseung Yoon, Kwanghee Baek
    Molecules and Cells.2020; 43(12): 975.     CrossRef
  • Convergent evolution on the hypoxia-inducible factor (HIF) pathway genes EGLN1 and EPAS1 in high-altitude ducks
    Allie M. Graham, Kevin G. McCracken
    Heredity.2019; 122(6): 819.     CrossRef
  • Inhibitory effects of plasmid small interfering RNA targeting signal transducer and activator of transcription‑3 in C6 glioma cells
    Jiajun Chen, Yue Zhou, Xiangyu Zhou, Jia Li, Feng Liu, Qingwei Zhou
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review
    Dongqing Guo, Colin E. Murdoch, Tianhua Liu, Jia Qu, Shihong Jiao, Yong Wang, Wei Wang, Xing Chen
    Frontiers in Pharmacology.2018;[Epub]     CrossRef
  • ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications
    Danbi Lee, Myoung-Kuk Jang, Ji Hae Seo, Soo Hyung Ryu, Jeong A. Kim, Young-Hwa Chung
    Experimental & Molecular Medicine.2018; 50(7): 1.     CrossRef
  • Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium
    Vinod Nadella, Sandhya Singh, Aklank Jain, Manju Jain, Karen M. Vasquez, Ashok Sharma, Pranay Tanwar, Goura Kishore Rath, Hridayesh Prakash
    Molecular Carcinogenesis.2018; 57(11): 1664.     CrossRef
  • HIF-1 as a Marker of Age-Related Diseases Associated with Tissue Hypoxia
    E. S. Popravka, N. S. Linkova, S. V. Trofimova, V. Kh. Khavinson
    Biology Bulletin Reviews.2018; 8(6): 497.     CrossRef
  • HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer
    Satoshi Sugita, Hideki Enokida, Hirofumi Yoshino, Kazutaka Miyamoto, Masaya Yonemori, Takashi Sakaguchi, Yoichi Osako, Masayuki Nakagawa
    International Journal of Oncology.2018;[Epub]     CrossRef
  • HIF-1α contributes to tube malformation of human lymphatic endothelial cells by upregulating VEGFR-3
    Tao Han, Jun Yan, Haini Chen, Yi Ji, Jianbing Chen, Jie Cui, Weimin Shen, Jijun Zou
    International Journal of Oncology.2018;[Epub]     CrossRef
  • Silencing Ubc9 expression suppresses osteosarcoma tumorigenesis and enhances chemosensitivity to HSV-TK/GCV by regulating connexin�43 SUMOylation
    Dianying Zhang, Kai Yu, Zhong Yang, Yanxia Li, Xiaofang Ma, Xiyun Bian, Fengting Liu, Lili Li, Xiaozhi Liu, Wenhan Wu
    International Journal of Oncology.2018;[Epub]     CrossRef
  • BP-1T, an antiangiogenic benzophenone-thiazole pharmacophore, counteracts HIF-1 signalling through p53/MDM2-mediated HIF-1α proteasomal degradation
    Prabhu Thirusangu, V. Vigneshwaran, T. Prashanth, B. R. Vijay Avin, Vikas H. Malojirao, H. Rakesh, Shaukath Ara Khanum, Riaz Mahmood, B. T. Prabhakar
    Angiogenesis.2017; 20(1): 55.     CrossRef
  • Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories
    Anthony R. Martin, Cyril Ronco, Luc Demange, Rachid Benhida
    MedChemComm.2017; 8(1): 21.     CrossRef
  • A tumoural angiogenic gateway blocker, Benzophenone-1B represses the HIF-1α nuclear translocation and its target gene activation against neoplastic progression
    Prabhu Thirusangu, V. Vigneshwaran, V. Lakshmi Ranganatha, B.R. Vijay Avin, Shaukath Ara Khanum, Riaz Mahmood, K. Jayashree, B.T. Prabhakar
    Biochemical Pharmacology.2017; 125: 26.     CrossRef
  • Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
    Ming Yue Li, Chunliu Mi, Ke Si Wang, Zhe Wang, Hong Xiang Zuo, Lian Xun Piao, Guang Hua Xu, Xuezheng Li, Juan Ma, Xuejun Jin
    Chemico-Biological Interactions.2017; 274: 58.     CrossRef
  • Nuclear translocation of HIF-1α induced by influenza A (H1N1) infection is critical to the production of proinflammatory cytokines
    Xinkun Guo, Zhaoqin Zhu, Wanju Zhang, Xiaoxiao Meng, Yong Zhu, Peng Han, Xiaohui Zhou, Yunwen Hu, Ruilan Wang
    Emerging Microbes & Infections.2017; 6(1): 1.     CrossRef
  • Hypoxia-inducible factor-1α in Antarctic notothenioids contains a polyglutamine and glutamic acid insert that varies in length with phylogeny
    A. S. Rix, T. J. Grove, K. M. O’Brien
    Polar Biology.2017; 40(12): 2537.     CrossRef
  • 125I seed irradiation induces apoptosis and inhibits angiogenesis by decreasing HIF-1α and VEGF expression in lung carcinoma xenografts
    Gui-Ling Xiang, Xin-Hong Zhu, Cun-Zhi Lin, Li-Jun Wang, Yong Sun, Yi-Wei Cao, Fang-Fang Wang
    Oncology Reports.2017; 37(5): 3075.     CrossRef
  • Forkhead Transcription Factor FOXO1 Inhibits Angiogenesis in Gastric Cancer in Relation to SIRT1
    Sue Youn Kim, Young San Ko, Jinju Park, Yiseul Choi, Jong-Wan Park, Younghoon Kim, Jung-Soo Pyo, Young Bok Yoo, Jae-Seon Lee, Byung Lan Lee
    Cancer Research and Treatment.2016; 48(1): 345.     CrossRef
  • Aryl Hydrocarbon Receptor Activates NDRG1 Transcription under Hypoxia in Breast Cancer Cells
    En-Yu Li, Wei-Yung Huang, Ya-Chu Chang, Mong-Hsun Tsai, Eric Y. Chuang, Qian-Yu Kuok, Shih-Ting Bai, Lo-Yun Chao, Yuh-Pyng Sher, Liang-Chuan Lai
    Scientific Reports.2016;[Epub]     CrossRef
  • Transcriptional regulation of human and murine short-chain dehydrogenase/reductases (SDRs) – anin silicoapproach
    Bettina Ebert, Michael Kisiela, Edmund Maser
    Drug Metabolism Reviews.2016; 48(2): 183.     CrossRef
  • Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma
    Mingxiao Lang, Xiuchao Wang, Hongwei Wang, Jie Dong, Chungen Lan, Jihui Hao, Chongbiao Huang, Xin Li, Ming Yu, Yanhui Yang, Shengyu Yang, He Ren
    Cancer Letters.2016; 378(2): 87.     CrossRef
  • Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68)
    Cheryl de Vallière, Jesus Cosin-Roger, Simona Simmen, Kirstin Atrott, Hassan Melhem, Jonas Zeitz, Mehdi Madanchi, Irina Tcymbarevich, Michael Fried, Gerd A. Kullak-Ublick, Stephan R. Vavricka, Benjamin Misselwitz, Klaus Seuwen, Carsten A. Wagner, Jyrki J.
    Cellular and Molecular Gastroenterology and Hepatology.2016; 2(6): 796.     CrossRef
  • Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models
    J. P. Phelan, F. J. Reen, N. Dunphy, R. O’Connor, F. O’Gara
    BMC Cancer.2016;[Epub]     CrossRef
  • Better Living through Chemistry: Caloric Restriction (CR) and CR Mimetics Alter Genome Function to Promote Increased Health and Lifespan
    Zoe E. Gillespie, Joshua Pickering, Christopher H. Eskiw
    Frontiers in Genetics.2016;[Epub]     CrossRef
  • Folic Acid Represses Hypoxia-Induced Inflammation in THP-1 Cells through Inhibition of the PI3K/Akt/HIF-1α Pathway
    Xiaoyan Huang, Zhiying He, Xinwei Jiang, Mengjun Hou, Zhihong Tang, Xiaozhou Zhen, Yuming Liang, Jing Ma, George Simos
    PLOS ONE.2016; 11(3): e0151553.     CrossRef
  • Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1α expression during tumor progression
    Woom-Yee Bae, Jae-Sun Choi, Ja-Eun Kim, Joo-Won Jeong
    Biochemical Pharmacology.2015; 98(1): 41.     CrossRef
  • Clinicopathological Significance of MicroRNA-20b Expression in Hepatocellular Carcinoma and Regulation of HIF-1αand VEGF Effect on Cell Biological Behaviour
    Tong-min Xue, Li-de Tao, Miao Zhang, Jie Zhang, Xia Liu, Guo-feng Chen, Yi-jia Zhu, Pei-Jian Zhang
    Disease Markers.2015; 2015: 1.     CrossRef
  • HIF-1α Contributes to Proliferation and Invasiveness of Neuroblastoma Cells via SHH Signaling
    Sheng Chen, Min Zhang, Lili Xing, Yue Wang, Yongtao Xiao, Yeming Wu, Sharmila Shankar
    PLOS ONE.2015; 10(3): e0121115.     CrossRef
  • Autoacetylation regulates differentially the roles of ARD1 variants in tumorigenesis
    JI HAE SEO, JI-HYEON PARK, EUN JI LEE, TAM THUY LU VO, HOON CHOI, JAE KYUNG JANG, HEE-JUN WEE, BUM JU AHN, JONG-HO CHA, MIN WOOK SHIN, KYU-WON KIM
    International Journal of Oncology.2015; 46(1): 99.     CrossRef
  • Transcriptome sequencing revealed differences in the response of renal cancer cells to hypoxia and CoCl2 treatment
    Nadezhda Zhigalova, Artem Artemov, Alexander M. Mazur, Egor B. Prokhortchouk
    F1000Research.2015; 4: 1518.     CrossRef
  • The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
    Dongjun Luo, Zhongxia Wang, Junyi Wu, Chunping Jiang, Junhua Wu
    BioMed Research International.2014; 2014: 1.     CrossRef
  • Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer
    Kelie M Reece, Emily D Richardson, Kristina M Cook, Tessa J Campbell, Stephen T Pisle, Alesia J Holly, David J Venzon, David J Liewehr, Cindy H Chau, Douglas K Price, William D Figg
    Molecular Cancer.2014;[Epub]     CrossRef
  • Exploring the Modulation of Hypoxia-Inducible Factor (HIF)-1α by Volatile Anesthetics as a Possible Mechanism Underlying Volatile Anesthetic-Induced CNS Injury
    Emma K. Giles, Andrew J. Lawrence, Jhodie R. Duncan
    Neurochemical Research.2014; 39(9): 1640.     CrossRef
  • Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus
    H Fan, F Liu, G Dong, D Ren, Y Xu, J Dou, T Wang, L Sun, Y Hou
    Cell Death & Disease.2014; 5(9): e1416.     CrossRef
  • Sleep apnoea and cancer: the new challenge
    Patrick Lévy, Diane Godin-Ribuot, Jean-Louis Pepin
    European Respiratory Journal.2014; 43(6): 1567.     CrossRef
  • [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer
    Ryusuke Takebayashi, Kunihiko Izuishi, Yuka Yamamoto, Reiko Kameyama, Hirohito Mori, Tsutomu Masaki, Yasuyuki Suzuki
    Journal of Experimental & Clinical Cancer Research.2013;[Epub]     CrossRef
  • The influence of pH and hypoxia on tumor metastasis
    Mariam Abaza, Yunus A Luqmani
    Expert Review of Anticancer Therapy.2013; 13(10): 1229.     CrossRef
  • Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
    Yan Xia, Hyun-Kyung Choi, Kyeong Lee
    European Journal of Medicinal Chemistry.2012; 49: 24.     CrossRef
  • Molecular Mechanism Underlying the Detection of Colorectal Cancer by 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography
    Kunihiko Izuishi, Yuka Yamamoto, Takanori Sano, Ryusuke Takebayashi, Yoshihiro Nishiyama, Hirohito Mori, Tsutomu Masaki, Asahiro Morishita, Yasuyuki Suzuki
    Journal of Gastrointestinal Surgery.2012; 16(2): 394.     CrossRef
  • A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κB promotes gastric tumour growth and angiogenesis
    S Y Nam, Y S Ko, J Jung, J Yoon, Y H Kim, Y J Choi, J W Park, M S Chang, W H Kim, B L Lee
    British Journal of Cancer.2011; 104(1): 166.     CrossRef
  • Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules
    Sue Youn Kim, Jiyeon Yoon, Young San Ko, Mee Soo Chang, Jong-Wan Park, Hee Eun Lee, Min A Kim, Ji Hun Kim, Woo Ho Kim, Byung Lan Lee
    BMC Cancer.2011;[Epub]     CrossRef
  • Terpestacin Inhibits Tumor Angiogenesis by Targeting UQCRB of Mitochondrial Complex III and Suppressing Hypoxia-induced Reactive Oxygen Species Production and Cellular Oxygen Sensing
    Hye Jin Jung, Joong Sup Shim, Jiyong Lee, Young Mi Song, Ki Chung Park, Seung Hoon Choi, Nam Doo Kim, Jeong Hyeok Yoon, Paul T. Mungai, Paul T. Schumacker, Ho Jeong Kwon
    Journal of Biological Chemistry.2010; 285(15): 11584.     CrossRef
  • The Clinicopathological Significance of Tissue Levels of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor in Gastric Cancer
    Seong-Eun Kim, Ki-Nam Shim, Sung-Ae Jung, Kwon Yoo, Joo Ho Lee
    Gut and Liver.2009; 3(2): 88.     CrossRef
  • 31,259 View
  • 642 Download
  • 80 Crossref
Close layer
Original Articles
Prospective Phase II Study of Preoperative Chemoradiation with Capecitabine in Locally Advanced Rectal Cancer
Jin-hong Park, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Seong Soo Shin, Jin Cheon Kim, Chang Sik Yu, Hee Cheol Kim, Yoon-Koo Kang, Tae Won Kim, Heung Moon Chang, Min Hee Ryu, Eun Kyung Choi
Cancer Res Treat. 2004;36(6):354-359.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.354
AbstractAbstract PDFPubReaderePub
Purpose

Capecitabine is an attractive oral chemotherapeutic agent that has a radiosensitizing effect and tumor-selectivity. This study was performed to evaluate the efficacy and toxicity of preoperative chemoradiation therapy, when used with oral capecitabine, for locally advanced rectal cancer.

Materials and Methods

A prospective phase II trial of preoperative chemoradiation for locally advanced adenocarcinomas of the lower two-thirds of the rectum was conducted. A radiation dose of 50 Gy over five weeks and a daily dose of 1650 mg/m2 capecitabine in two potions was administered during the entire course of radiation therapy. Surgery was performed with standardized total mesorectal excision four to six weeks after completion of the chemoradiation.

Results

Between January 2002 and September 2003, 61 patients were enrolled onto this prospective phase II trial. The pretreatment clinical stages were T3 in 64% (n=39), T4 in 36% (n=22) and N1-2 in 82% (n=50) of these patients. Fifty-six (92%) patients completed the chemoradiation as initially planned and a complete resection performed in 58 (95%). Down-staging was observed in 45 patients (74%) and a pathologic complete response in 6 (10%). Among the 37 patients with tumors located within 5 cm from the anal verge on colonoscopy, 27 (73%) underwent a sphincter-preserving procedure. No grade 3 and 4 proctitis or hematological toxicities were observed.

Conclusion

Preoperative chemoradiation therapy with capecitabine achieved encouraging rates of tumor downstaging and sphincter preservation, with a low toxicity profile. This combined modality can be regarded as a safe and effective treatment for locally advanced rectal cancer.

Citations

Citations to this article as recorded by  
  • MRI for Rectal Cancer: Staging, mrCRM, EMVI, Lymph Node Staging and Post-Treatment Response
    David D.B. Bates, Maria El Homsi, Kevin J. Chang, Neeraj Lalwani, Natally Horvat, Shannon P. Sheedy
    Clinical Colorectal Cancer.2022; 21(1): 10.     CrossRef
  • MRI of Rectal Cancer: An Overview and Update on Recent Advances
    Kartik S. Jhaveri, Hooman Hosseini-Nik
    American Journal of Roentgenology.2015; 205(1): W42.     CrossRef
  • Current Controversies in Neoadjuvant Chemoradiation of Rectal Cancer
    P. Terry Phang, Xiaodong Wang
    Surgical Oncology Clinics of North America.2014; 23(1): 79.     CrossRef
  • Tailored rectal cancer treatment – a time for implementing contemporary prognostic factors?
    A. Wibe, W. L. Law, V. Fazio, C. P. Delaney
    Colorectal Disease.2013; 15(11): 1333.     CrossRef
  • Oncologic Outcome After Preoperative Chemoradiotherapy in Patients With Pathologic T0 (ypT0) Rectal Cancer
    Tae Young Jang, Chang Sik Yu, Yong Sik Yoon, Seok-Byung Lim, Seung-Mo Hong, Tae Won Kim, Jong Hoon Kim, Jin Cheon Kim
    Diseases of the Colon & Rectum.2012; 55(10): 1024.     CrossRef
  • Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
    J G Kim, S K Sohn, D H Kim, J H Baek, S B Jeon, Y S Chae, K B Lee, J S Park, J H Sohn, J C Kim, I K Park
    British Journal of Cancer.2005; 93(10): 1117.     CrossRef
  • Preoperative Concurrent Chemoradiotherapy with Oral Fluoropyrimidine in Locally Advanced Rectal Cancer: How Good Is Good Enough?
    Hyun Cheol Chung
    Cancer Research and Treatment.2004; 36(6): 341.     CrossRef
  • 10,526 View
  • 53 Download
  • 7 Crossref
Close layer
Responsiveness of CPT-11 in Respect to hMLH1 and hMSH2 Protein Expression in the Primary Colorectal Cancer
In Ja Park, Hee Cheol Kim, Chang Sik Yu, Heung Moon Chang, Jea Hwan Lee, Jong Hoon Kim, Tae Won Kim, Jung Sun Kim, Jin Cheon Kim
Cancer Res Treat. 2004;36(6):360-366.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.360
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to evaluate the responsiveness to CPT-11 with respect to hMLH1 and hMSH2 protein expressions in primary colorectal tumors.

Materials and Methods

91 patients with colorectal cancer treated having undergone surgery and postoperative CPT-11-based adjuvant chemotherapy, between 1997 and 2002, were prospectively recruited. Tumor samples were immunohistochemically analyzed for the expressions of hMLH1, hMSH2, p53 and CEA proteins.

Results

Of the 91 tumors, 6 (6.6%) and 4 (4.4%) showed loss of hMLH1 and hMSH2 protein expressions, respectively. The response rate of patients with tumors not expressing either hMLH1 or hMSH2 was higher than that of those expressing either of these proteins (p=0.026). Patients with tumors not expressing hMLH1 showed a significantly better response to CPT-11 (p=0.04). The responsiveness was not associated with the expressions of hMSH2, p53 or CEA. There were no correlations between drug toxicity and the expressions of hMLH1, hMSH2 or p53. The overall survival was better in patients responsive to CPT-11-based chemotherapy compared to non-responders.

Conclusion

The immunohistochemical determination of loss of hMLH1 and hMSH2 expressions may be used in determining the responsiveness to CPT-11-based chemotherapy. Our results suggest that hMLH1 protein expression may be a predictor for CPT-11 responsiveness in patients with colorectal cancer.

  • 7,089 View
  • 29 Download
Close layer
The Efficacy of Docetaxel and Cisplatin Combination Chemotherapy for the Treatment of Advanced Gastric Cancer after Failing to 5-Fluorouracil Based Chemotherapy
Sang-Joon Shin, Min-Kyoung Kim, Kyung-Hee Lee, Myung-Soo Hyun, Sang Woon Kim, Sun Kyo Song, Sung-Hwa Bae, Hun-Mo Ryoo
Cancer Res Treat. 2004;36(6):367-371.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.367
AbstractAbstract PDFPubReaderePub
Purpose

This study was conducted to confirm the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy (DP) in patients with advanced gastric cancer.

Materials and Methods

Patients with measurable gastric adenocarcinoma received intravenous docetaxel 75 mg/m2 and cisplatin 75 mg/m2 with premedication on day 1, which was repeated every 3 weeks. All patients received DP as a second-line treatment after failing to 5-FU based chemotherapy.

Results

34 patients were enrolled in this study between January 1998 and August 2003. A total of 112 cycles (median 3 cycles) were administered. Responses were evaluable in 30 patients. The objective response rate was 16.7% (95% CI: 3.5~30.3), with a stable disease in 56.7% (95% CI: 40.0~74.4) and a progressive disease in 26.7% (95% CI: 10.9~42.5) of patients, with a median follow up duration of 20 months for all the patients, The median duration of response, time to progression and overall survival were 2.1 months (95% CI: 0.4~3.9), 4.2 months (95% CI: 2.3~6.1) and 6.8 months (95% CI: 1.3~12.3), respectively, with a 1-year survival rate of 32%. The toxicity was evaluated in 30 patients, with neutropenia being most common. Renal impairment was seen in two patients with grade 3 creatinine elevation and liver enzyme elevation in four with grades 3 and 4.

Conclusion

Although DP was an active combination regimen, with a tumor control rate of about 73% and with moderate tolerance, adjustment of the administration schedule, with further evaluation of other combination chemotherapies of docetaxel with new agents, other than cisplatin, seem warranted.

Citations

Citations to this article as recorded by  
  • Neoadjuvant chemotherapy for gastric cancer: A meta‐analysis of randomized, controlled trials
    Yi Liao, Zu‐li Yang, Jun‐sheng Peng, Jun Xiang, Jian‐ping Wang
    Journal of Gastroenterology and Hepatology.2013; 28(5): 777.     CrossRef
  • Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
    Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung
    Cancer Chemotherapy and Pharmacology.2007; 61(1): 157.     CrossRef
  • A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Seung Tai Kim, Joon Oh Park, Jeeyun Lee, Kyu Taek Lee, Jong Kyun Lee, Seong-Ho Choi, Jin-Seok Heo, Young Suk Park, Won Ki Kang, Keunchil Park
    Cancer.2006; 106(6): 1339.     CrossRef
  • Isolated tumor cells in lymph nodes are not a prognostic marker for patients with stage I and stage II colorectal cancer
    Min Ro Lee, Chang Won Hong, Sang Nam Yoon, Seok-Byung Lim, Kyu Joo Park, Min Jin Lee, Woo Ho Kim, Jae-Gahb Park
    Journal of Surgical Oncology.2006; 93(1): 13.     CrossRef
  • Radical Radiotherapy for Locally Advanced Cancer of Uterine Cervix
    Jeung Eun Lee, Seung Jae Huh, Won Park, Do Hoon Lim, Yong Chan Ahn, Chang Soo Park, Byoung Gie Kim, Duk Soo Bae, Je Ho Lee, Chong Taik Park, Tae Jin Kim, Kyung Taek Lim, Hwan Wook Chung, Ki Heon Lee, Jae Uk Shim
    Cancer Research and Treatment.2004; 36(4): 222.     CrossRef
  • 8,241 View
  • 46 Download
  • 5 Crossref
Close layer
Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients
Jin-Soo Kim, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang-Il Kim, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
Cancer Res Treat. 2004;36(6):372-376.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.372
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study is to compare the antiemetic efficacy and tolerability of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed emesis.

Material and Methods

From April 2002 through October 2002, a total of 112 patients receiving cisplatin- based combination chemotherapy were randomized to receive a single i.v. dose of dolasetron 100 mg or ondansetron 8 mg, 30 minutes before the initiation of chemotherapy. In the ondansetron group, two additional doses of ondansetron 8 mg were given at intervals of 2 to 4 hours. To prevent delayed emesis, dolasetron 200 mg p.o. daily or ondansetron 8 mg p.o. bid was administered from the 2nd days to a maximum of 5 days. The primary end point was the proportion of patients that experienced no emetic episodes and required no rescue medication (complete response, CR) during the 24 hours (acute period) and during Day 2 to Day 5±2 days (delayed period), after chemotherapy. The secondary end points included the incidence and severity of emesis.

Results

105 patients were evaluable for efficacy. CR rates during the acute period were 36.0% for a single dose of dolasetron 100 mg, and 43.6% for three doses of ondansetron 8 mg. CR rates during the delayed period were 8.0% and 10.9%, respectively. There was no significant difference in the efficacy between the two groups. Adverse effects were mostly mild to moderate and not related to study medication.

Conclusions

A single i.v. dose of dolasetron 100 mg is as effective as three i.v. doses of ondansetron 8 mg in preventing acute and delayed emesis after cisplatin-based chemotherapy, with a comparable safety profile.

Citations

Citations to this article as recorded by  
  • Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
    Giovana Paula Rezende Simino, Lays Pires Marra, Eli Iola Gurgel de Andrade, Francisco de Assis Acúrcio, Ilka Afonso Reis, Vânia Eloisa De Araújo, Mariângela Leal Cherchiglia
    Expert Review of Clinical Pharmacology.2016; 9(9): 1183.     CrossRef
  • Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review
    Andrea C Tricco, Charlene Soobiah, Wing Hui, Jesmin Antony, Vladi Struchkov, Brian Hutton, Brenda Hemmelgarn, David Moher, Sharon E Straus
    BMC Pharmacology and Toxicology.2015;[Epub]     CrossRef
  • 9,654 View
  • 52 Download
  • 2 Crossref
Close layer
An Analysis of the Risk Factors and Management of Lymphocele after Pelvic Lymphadenectomy in Patients with Gynecologic Malignancies
Hee Yeon Kim, Jae Wook Kim, Sung Hoon Kim, Young Tae Kim, Jae Hoon Kim
Cancer Res Treat. 2004;36(6):377-383.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.377
AbstractAbstract PDFPubReaderePub
Objectives

The incidence and risk factors of lymphocele development after pelvic lymphadenectomy were evaluated and its management investigated.

Materials and Methods

This retrospective study was carried out on 264 patients who received a pelvic lymphadenectomy, between March 1999 and February 2003, due to gynecologic cancer. The patients were classified into two groups; the lymphocele (n=50) and non-lymphocele groups (n=214), as confirmed by ultrasonography, CT scan and MRI. Each group was compared by cancer type and stage, BMI, preoperative Hb, use of pre/postoperative chemotherapy or radiotherapy, number of resected pelvic lymph nodes and the volume of postoperative drainage from a Hemovac® pelvic drain.

Results

Of the 264 patients tested, 15 of 105 cervical cancer (14%), 22 of 115 ovarian cancer (19%) and 11 of 40 endometrial cancer patients (27%), a total of 50 patients (18%), developed lymphoceles. In the lymphocele group (n=50), 13 patients were diagnosed with complicated lymphocele. The BMI and number of resected pelvic lymph nodes were found to be higher in the lymphocele than in the non-lymphocele group (23.94±3.38 vs. 22.52±3.00, p=0.00 and 26.80±14.82 vs. 22.96±10.18, p=0.03, respectively), and showed statistical significance. The occurrence of lymphoceles was lower without postoperative radiotherapy (p=0.01).

Conclusion

Among the 264 patients, a total of 50 patients (18%) developed lymphoceles. The BMI and number of resected lymph nodes were higher in the lymphocele group, and the use of postoperative radiotherapy was associated with a higher risk of lymphoceles. Thirteen of the 50 patients that developed lymphoceles (n=50) required treatment for lymphocele-related complications.

Citations

Citations to this article as recorded by  
  • Postoperative Morbidity and Factors Predicting the Development of Lymphoceles Following Lateral Pelvic Node Dissection for Rectal Cancer: A Cohort Study
    Joseph Mathew, Mufaddal Kazi, Ashwin Desouza, Avanish Saklani
    Annals of Surgical Oncology.2025; 32(1): 165.     CrossRef
  • Advances and Techniques in Medical Imaging and Minimally Invasive Interventions for Disorders of the Central Conducting and Mesenteric Lymphatic System
    Frederic J. Bertino, Kin Fen Kevin Fung
    Lymphatics.2025; 3(1): 8.     CrossRef
  • Risk factors for lymph ascites after surgery for endometrial cancer and impact on lymphedema of the legs. A prospective longitudinal Swedish multicenter study
    Madelene Wedin, Karin Glimskär Stålberg, Ulrika Ottander, Åsa Åkesson, Gabriel Lindahl, Ninnie Borendal Wodlin, Preben Kjølhede
    Acta Obstetricia et Gynecologica Scandinavica.2025; 104(5): 976.     CrossRef
  • Postoperative lymphatic leakage following laparoscopic totally extraperitoneal inguinal hernia repair: the first case report and review of the literature
    N. Kapellas, S. Alkhalil, T. Hero, M. Senkal
    Hernia.2025;[Epub]     CrossRef
  • Intra‐lymphocele microsurgical identification of causative afferent vessels for effective lymphaticovenular anastomosis in lymphocele treatment: A case report
    Kohei Mitsui, Mitsunaga Narushima, Kanako Danno, Ryohei Ishiura, Chihena H. Banda
    Microsurgery.2024;[Epub]     CrossRef
  • Symptomatic Lymphocele After Robot-Assisted Pelvic Lymphadenectomy as Part of the Primary Surgical Treatment for Cervical and Endometrial Cancer: A Retrospective Cohort Study
    Alise de Jong, Ilse G.T. Baeten, Anna Jansen, Jacob P. Hoogendam, Ina M. Jürgenliemk–Schulz, Ronald P. Zweemer, Cornelis G. Gerestein
    Journal of Minimally Invasive Gynecology.2024; 31(3): 243.     CrossRef
  • Vascular Clips for Preventing Lymphocele and Symptomatic Lymphocele in Patients With Gynecologic Malignancies After Laparoscopic Pelvic Lymphadenectomy
    Luyang Zhao, Xiufeng Xie, Wensheng Fan, Yang Wen, Nina Zhang, Jia Xu, Yuanguang Meng, Chenglei Gu
    Journal of Minimally Invasive Gynecology.2024; 31(10): 875.     CrossRef
  • Compression Neuropathy Caused by Pelvic Lymphocele after Laparoscopic Surgical Staging
    Dong Jin Chae, Jong Bum Park, Mi Jin Hong, Jungyun Kim, Cho E. Sim, Seung-Eun Kim, Yung Jin Lee
    Journal of Electrodiagnosis and Neuromuscular Diseases.2024; 26(2): 29.     CrossRef
  • Long-term outcomes of sentinel lymph node navigation surgery for early-stage cervical cancer
    Shinichi Togami, Nozomi Furuzono, Mika Mizuno, Shintaro Yanazume, Hiroaki Kobayashi
    International Journal of Clinical Oncology.2024; 29(11): 1740.     CrossRef
  • Lymphatic embolization for early post-operative lymphatic leakage after radical cystectomy for bladder cancer
    Yoo Sub Shin, Kichang Han, Jongsoo Lee, Hyun Ho Han, Won Sik Jang, Gyoung Min Kim, Ji Eun Heo, Mazyar Zahir
    PLOS ONE.2024; 19(9): e0305240.     CrossRef
  • Incomplete lymphatic sealing around the inferior mesenteric artery is a risk factor for chylous ascites in robotic rectal cancer surgery
    Hajime Ushigome, Hiroki Takahashi, Anri Maeda, Akira Kato, Shinnosuke Harata, Kawori Watanabe, Takeshi Yanagita, Takuya Suzuki, Kazuyoshi Shiga, Koshiro Harata, Ryo Ogawa, Yoichi Matsuo, Akira Mitsui, Masahiro Kimura, Shuji Takiguchi
    Asian Journal of Endoscopic Surgery.2023; 16(2): 163.     CrossRef
  • A Prospective Observational Study to Know the Origin of Lymphorrhea in Post-Renal Transplant Patients using Creatine Phosphokinase and Lactate Dehydrogenase
    Eeshansh Khare, Debansu Sarkar, Debojyoti Bhattacharjee, Dilip Kumar Pal
    Indian Journal of Transplantation.2023; 17(2): 215.     CrossRef
  • Lymphatic Complications Following Sentinel Node Biopsy or Pelvic Lymphadenectomy for Endometrial Cancer
    Shinichi Terada, Tomohito Tanaka, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Atsushi Daimon, Shunsuke Miyamoto, Ruri Nishie, Shoko Ueda, Sousuke Hashida, Natsuko Morita, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Taniguchi, Kazumasa K
    Journal of Clinical Medicine.2023; 12(13): 4540.     CrossRef
  • The incidence of perioperative lymphatic complications after radical hysterectomy and pelvic lymphadenectomy between robotic and laparoscopic approach : a systemic review and meta-analysis
    Jong Ha Hwang, Bo Wook Kim
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Vacuum-Assisted Suction Drainage as a Successful Treatment Option for Postoperative Symptomatic Lymphoceles
    Mareike Franke, Christian Saager, Jan-Robert Kröger, Jan Borggrefe, Kersten Mückner
    RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2022; 194(04): 384.     CrossRef
  • The incidence of postoperative symptomatic lymphocele after pelvic lymphadenectomy between abdominal and laparoscopic approach: a systemic review and meta-analysis
    Jong Ha Hwang, Bo Wook Kim
    Surgical Endoscopy.2022; 36(10): 7114.     CrossRef
  • Lymphatic Interventions in the Cancer Patient
    Eslam Wassal Youssef, Ahmed Aly, Akshaar Brahmbhatt, Amgad Moussa, Ernesto Santos
    Current Oncology Reports.2022; 24(10): 1351.     CrossRef
  • Difficult-to-treat Retroperitoneal Lymphocele Following Oblique Lumbar Interbody Fusion―A Case Report―
    Motonori Ishii, Masahito Hara, Yu Yamamoto, Mamoru Matsuo, Hiroshi Ito, Daimon Shiraishi, Masataka Ando, Masakazu Takayasu
    Spinal Surgery.2022; 36(1): 66.     CrossRef
  • Impact of Sentinel Node Mapping in Decreasing the Risk of Lymphocele in Endometrial Cancer
    Thiago Pereira Diniz, Eric Drizlionoks, Carlos Chaves Faloppa, Jacqueline Nunes Menezes, Henrique Mantoan, Bruna Tirapelli Gonçalves, Paulo Henrique Domingues Miranda Brandao, Lillian Yuri Kumagai, Levon Badiglian-Filho, Alexandre Andre Balieiro Anastacio
    Annals of Surgical Oncology.2021; 28(6): 3293.     CrossRef
  • Fistula formation between infected pelvic lymphocele and sigmoid colon: A rare complication of pelvic lymphadenectomy
    Soukaina Allioui, Sanae Sninate, Hounayda Jerguigue, Rachida Latib, Youssef Omor
    Radiology Case Reports.2021; 16(3): 707.     CrossRef
  • Managing infected seroma post-lymphadenectomy; A retrospective cohort study and cost analysis in melanoma patients
    A.V. Robinson, F. Ali, D.J. Dewar, A.H.S. Peach
    Journal of Plastic, Reconstructive & Aesthetic Surgery.2021; 74(9): 2251.     CrossRef
  • Recommendations and Clinical Validation of Inguinal Clinical Target Volume Delineation in Penile Cancer
    Rishi Mittal, Rahul Krishnatry, Priyamvada Maitre, Vedang Murthy
    International Journal of Radiation Oncology*Biology*Physics.2021; 111(3): 741.     CrossRef
  • Comparison of lymphatic complications between sentinel node navigation surgery and pelvic lymphadenectomy in patients with cervical cancer
    Shinichi Togami, Rintaro Kubo, Toshihiko Kawamura, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
    Japanese Journal of Clinical Oncology.2020; 50(5): 543.     CrossRef
  • Treatment of lymphocele with negative pressure wound therapy post inguinal mass excision: A case-report
    Caio Cesar Martins Focássio, Ricardo Augusto Bravo Gamboa, Luis Felipe Staut de Marco, Daniela Mina Fukasawa, Talita da Silva Parente, Vitor Leoni Boher Lopes Dornas
    International Journal of Surgery Case Reports.2020; 66: 43.     CrossRef
  • Incidence of and risk factors for lymphocele formation after lateral pelvic lymph node dissection for rectal cancer: a retrospective study
    K. Ochiai, M. Kaneko, H. Nozawa, K. Kawai, K. Hata, T. Tanaka, T. Nishikawa, Y. Shuno, K. Sasaki, M. Hiyoshi, S. Emoto, K. Murono, H. Sonoda, S. Ishihara
    Colorectal Disease.2020; 22(2): 161.     CrossRef
  • Early Postoperative Complications and Outcomes of Kidney Transplantation in Moderately Obese Patients
    Karola Warzyszyńska, Michał Zawistowski, Edyta Karpeta, Agata Ostaszewska, Maurycy Jonas, Maciej Kosieradzki
    Transplantation Proceedings.2020; 52(8): 2318.     CrossRef
  • Predictive Factors of Deep Vein Thrombosis in Gynecologic Cancer Survivors with Lower Extremity Edema: A Single-Center and Retrospective Study
    Jungin Kim, Hyun-Jun Kim, Seunghun Park, Dong Kyu Kim, Tae Hee Kim
    Healthcare.2020; 8(1): 48.     CrossRef
  • Risk factors for lymphatic complications following lymphadenectomy in patients with endometrial cancer
    Shinichi Togami, Rintaro Kubo, Toshihiko Kawamura, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
    Taiwanese Journal of Obstetrics and Gynecology.2020; 59(3): 420.     CrossRef
  • Comparison of postoperative benign pelvic cysts occurred after gynecologic or gyne-oncologic surgery treated with percutaneous transcatheteric sclerosant alcohol therapy
    Cihan Comba, AysunErbahceci Salik, Gokhan Demirayak, SakirVolkan Erdogan, Filiz Sacan, IsaAykut Ozdemir
    Gynecology and Minimally Invasive Therapy.2020; 9(4): 198.     CrossRef
  • Distribution of lymphocele following lymphadenectomy in patients with gynecological malignancies
    Soo Youn Song, Mia Park, Byung Hun Kang, Jung Bo Yang, Young Bok Ko, Mina Lee, Ki Hwan Lee, Heon Jong Yoo
    Obstetrics & Gynecology Science.2020; 63(6): 700.     CrossRef
  • Combined treatment with lymphaticovenular anastomosis and ethanol sclerotherapy for femoral lymphocele with lymphedema after oncologic surgery
    Shuhei Yoshida, Isao Koshima, Hirofumi Imai, Ayano Sasaki, Shogo Nagamatsu, Kazunori Yokota
    Medicine: Case Reports and Study Protocols.2020; 1(1): e0007.     CrossRef
  • Decreasing Lymphoid Fluid Accumulation During Lymph-Node Dissection
    Tanitra Tantitamit, Kuan-Gen Huang, Lih-Lian Hwang
    Journal of Gynecologic Surgery.2019; 35(3): 129.     CrossRef
  • Lymphatic cysts after gynecological cancer surgery: risk factors, diagnosis and treatment
    Т. Т. Rogovskaya, I. V. Berlev
    Tumors of female reproductive system.2019; 14(4): 72.     CrossRef
  • Predictors of Lymphoceles in Women Who Underwent Laparotomic Retroperitoneal Lymph Node Dissection for Early Gynecologic Cancer: A Retrospective Cohort Study
    Hui-Hua Chen, Wan-Hua Ting, Ho-Hsiung Lin, Sheng-Mou Hsiao
    International Journal of Environmental Research and Public Health.2019; 16(6): 936.     CrossRef
  • Ultrasound characteristics of a symptomatic and asymptomatic lymphocele after pelvic and/or paraaortic lymphadenectomy
    Vit Weinberger, Daniela Fischerova, Ivana Semeradova, Jiri Slama, David Cibula, Michal Zikan
    Taiwanese Journal of Obstetrics and Gynecology.2019; 58(2): 266.     CrossRef
  • Bilateral hydronephrosis subsequent to a giant lymphocele after robotic radical prostatectomy
    Erdem Koç, Bahri Gök, Davut Kamacı, Erem Asil, Ali Fuat Atmaca
    Journal of Surgery and Medicine.2019;[Epub]     CrossRef
  • Manejo postoperatorio de cistectomía radical. Revisión de la evidencia sobre la prevención y el tratamiento de las complicaciones urológicas
    O. Rodríguez Faba, R. Parada Moreno, L. Malca, A. Palomino Martínez, N. Nervo, A. Breda, C. Esquinas, J. Palou
    Actas Urológicas Españolas.2018; 42(3): 143.     CrossRef
  • Sentinel lymph node biopsy in endometrial cancer—Feasibility, safety and lymphatic complications
    Barbara Geppert, Céline Lönnerfors, Michele Bollino, Jan Persson
    Gynecologic Oncology.2018; 148(3): 491.     CrossRef
  • Embolization Using N-butyl Cyanoacrylate for Postoperative Lymphatic Leakage: A Case Report
    Emina Kayama, Koshiro Nishimoto, Gou Kaneko, Suguru Shirotake, Taiki Hayashi, Hideyuki Kondo, Takashi Okabe, Ken Nakazawa, Masafumi Oyama
    Clinical Genitourinary Cancer.2018; 16(2): e355.     CrossRef
  • Postoperative management of radical cystectomy. Review of the evidence on the prevention and treatment of urological complications
    O. Rodríguez Faba, R. Parada Moreno, L. Malca, A. Palomino Martínez, N. Nervo, A. Breda, C. Esquinas, J. Palou
    Actas Urológicas Españolas (English Edition).2018; 42(3): 143.     CrossRef
  • Prospective Randomized Controlled Trial Exploring the Effect of TachoSil on Lymphocele Formation After Extended Pelvic Lymph Node Dissection in Prostate Cancer
    Sarah Buelens, Charles Van Praet, Filip Poelaert, Andries Van Huele, Karel Decaestecker, Nicolaas Lumen
    Urology.2018; 118: 134.     CrossRef
  • Risk factors, microbiology and management of infected lymphocyst after lymphadenectomy for gynecologic malignancies
    Xuegong Ma, Yingmei Wang, Aiping Fan, Mengting Dong, Xin Zhao, Xuhong Zhang, Fengxia Xue
    Archives of Gynecology and Obstetrics.2018; 298(6): 1195.     CrossRef
  • The role of pelvic lymphocele in the development of early postoperative complications
    Octavian Constantin Neagoe, Mihaela Ionica, Octavian Mazilu
    Medicine.2018; 97(37): e12353.     CrossRef
  • Risk factors for lymphatic complications following lymphadenectomy in patients with cervical cancer
    Shinichi Togami, Toshihiko Kawamura, Mika Fukuda, Shintaro Yanazume, Masaki Kamio, Hiroaki Kobayashi
    Japanese Journal of Clinical Oncology.2018; 48(12): 1036.     CrossRef
  • Microbiological evaluation of infected pelvic lymphocele after robotic prostatectomy: potential predictors for culture positivity and selection of the best empirical antimicrobial therapy
    Alaa Hamada, Catalina Hwang, Jorge Fleisher, Ingolf Tuerk
    International Urology and Nephrology.2017; 49(7): 1183.     CrossRef
  • Nomogram predicting risk of lymphocele in gynecologic cancer patients undergoing pelvic lymph node dissection
    Baraem Yoo, Hyojeong Ahn, Miseon Kim, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim
    Obstetrics & Gynecology Science.2017; 60(5): 440.     CrossRef
  • A successful case of a para-aortic lymphocele treated with autologous peripheral blood injection
    Keiji Nishibeppu, Tomohiro Arita, Masayoshi Nakanishi, Yoshiaki Kuriu, Yasutoshi Murayama, Katsutoshi Shoda, Toshiyuki Kosuga, Hirotaka Konishi, Ryo Morimura, Shuhei Komatsu, Atsushi Shiozaki, Hisashi Ikoma, Daisuke Ichikawa, Hitoshi Fujiwara, Kazuma Okam
    Radiology Case Reports.2017; 12(4): 760.     CrossRef
  • Retroperitoneal Lymphocele in a Patient with Primary Ovarian Cancer: A Case Report
    Leila Mousavi Seresht, Meysam Izadi, Zohreh Yousefi, Amir Hosein Jafarian, Nooshin Babapour, Laya Shirinzadeh, Zahra Rastin
    Journal of Obstetrics, Gynecology and Cancer Research.2017; 2(4): 1.     CrossRef
  • A review of the postoperative lymphatic leakage
    Shulan Lv, Qing Wang, Wanqiu Zhao, Lu Han, Qi Wang, Nasra Batchu, Qurat Ulain, Junkai Zou, Chao Sun, Jiang Du, Qing Song, Qiling Li
    Oncotarget.2017; 8(40): 69062.     CrossRef
  • Symptomatic Lymphocele Formation After Sentinel Lymph Node Biopsy for Early Stage Cervical Cancer
    Nasuh Utku Dogan, Nigar Garagozova, Tatiana Pfiffer, Anna Beier, Christhardt Köhler, Giovanni Favero
    Journal of Minimally Invasive Gynecology.2016; 23(3): 442.     CrossRef
  • Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization
    Tae-Wook Kong, Suk-Joon Chang, Jinoo Kim, Jiheum Paek, Su Hyun Kim, Je Hwan Won, Hee-Sug Ryu
    Journal of Gynecologic Oncology.2016;[Epub]     CrossRef
  • Use of TachoSil® to Prevent Symptomatic Lymphocele after an Aggressive Tumor Debulking with Lymphadenectomy for Advanced Stage Ovarian Cancer. A Pilot Study
    Lucas Minig, Maria Guadalupe Patrono, Jose Miguel Cárdenas-Rebollo, Pedro Martin Marfil, Virginia Rodriguez-Tabares, Linus Chuang
    Gynecologic and Obstetric Investigation.2016; 81(6): 497.     CrossRef
  • Radiotherapy in Prostate Cancer Patients With Pelvic Lymphocele After Surgery: Clinical and Dosimetric Data of 30 Patients
    Barbara Alicja Jereczek-Fossa, Sarah Pia Colangione, Cristiana Fodor, Stefania Russo, Raffaella Cambria, Dario Zerini, Maria Bonora, Agnese Cecconi, Barbara Vischioni, Andrea Vavassori, Deliu Victor Matei, Danilo Bottero, Antonio Brescia, Gennaro Musi, Fe
    Clinical Genitourinary Cancer.2015; 13(4): e223.     CrossRef
  • Optimal Timing for Drainage of Infected LymphocystsAfter Lymphadenectomy for Gynecologic Cancer
    Kosuke Hiramatsu, Eiji Kobayashi, Yutaka Ueda, Tomomi Egawa-Takata, Shinya Matsuzaki, Toshihiro Kimura, Kenjiro Sawada, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura
    International Journal of Gynecological Cancer.2015; 25(2): 337.     CrossRef
  • A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer
    Michal Zikan, Daniela Fischerova, Ivana Pinkavova, Jiri Slama, Vit Weinberger, Ladislav Dusek, David Cibula
    Gynecologic Oncology.2015; 137(2): 291.     CrossRef
  • Prevention of Lymphoceles Using FloSeal and CoSeal After Laparoscopic Lymphadenectomy in Patients With Gynecologic Malignancies
    Christhardt Köhler, Sarah Kyeyamwa, Simone Marnitz, Audrey Tsunoda, Filiberto Vercelino, Achim Schneider, Giovanni Favero
    Journal of Minimally Invasive Gynecology.2015; 22(3): 451.     CrossRef
  • Les lymphadénectomies dans le cancer de l’endomètre, bilan après 4ans de pratique, doit-on poursuivre ?
    Nicolas Agar, Anne-Cécile Philippe, Nicolas Bourdel, Benoît Rabischong, Michel Canis, Guillaume Le Bouedec, Aurélien Mulliez, Jacques Dauplat, Christophe Pomel
    Bulletin du Cancer.2015; 102(5): 428.     CrossRef
  • Impact of lymphoceles on organ at risk doses in patients undergoing adjuvant pelvic radiation for carcinoma cervix
    Chandani Hotwani, Supriya Chopra, Nara Moirangthem, Sarthak Mohanty
    International Journal of Cancer Therapy and Oncology.2015; 3(2): 3220.     CrossRef
  • Bleomycin Sclerotherapy for Severe Symptomatic and Persistent Pelvic Lymphocele
    Ana Sofia Fernandes, Antónia Costa, Raquel Mota, Vera Paiva
    Case Reports in Obstetrics and Gynecology.2014; 2014: 1.     CrossRef
  • Lymphocele: prevalence and management in gynecological malignancies
    Vit Weinberger, David Cibula, Michal Zikan
    Expert Review of Anticancer Therapy.2014; 14(3): 307.     CrossRef
  • Early Cervical Carcinoma and Fertility-sparing Treatment Options: MR Imaging as a Tool in Patient Selection and a Follow-up Modality
    Patricia Noël, Mireille Dubé, Marie Plante, Guillaume St-Laurent
    RadioGraphics.2014; 34(4): 1099.     CrossRef
  • Prevention of lymphocele development in gynecologic cancers by the electrothermal bipolar vessel sealing device
    Naotake Tsuda, Kimio Ushijima, Kouichiro Kawano, Shuji Takemoto, Shin Nishio, Gounosuke Sonoda, Toshiharu Kamura
    Journal of Gynecologic Oncology.2014; 25(3): 229.     CrossRef
  • Lymphocele after extraperitoneal robot‐assisted radical prostatectomy: A propensity score‐matching study
    Joo Yong Lee, Richilda Red Diaz, Kang Su Cho, Ho Song Yu, Jae Seung Chung, Won Sik Ham, Young Deuk Choi
    International Journal of Urology.2013; 20(12): 1169.     CrossRef
  • Ovarian Cystic Lesions
    Susan Ackerman, Abid Irshad, Madelene Lewis, Munazza Anis
    Radiologic Clinics of North America.2013; 51(6): 1067.     CrossRef
  • Acute Kidney Injury after a Pelvic Surgery
    Mototsugu Tanaka, Junichi Hirahashi, Takamoto Ohse, Toshiro Fujita
    Nephrology.2013; 18(1): 73.     CrossRef
  • Effective treatment of pelvic lymphocele by lymphaticovenular anastomosis
    Takeshi Todokoro, Dominic Furniss, Katsutoshi Oda, Kei Kawana, Mitsunaga Narushima, Makoto Mihara, Kazuki Kikuchi, Hisako Hara, Tetsu Yano, Isao Koshima
    Gynecologic Oncology.2013; 128(2): 209.     CrossRef
  • Complications of lymphadenectomy for gynecologic cancer
    A. Achouri, C. Huchon, A.S. Bats, C. Bensaid, C. Nos, F. Lécuru
    European Journal of Surgical Oncology (EJSO).2013; 39(1): 81.     CrossRef
  • Idiopathic Lymphocele: A Possible Diagnosis for Infraclavicular Masses
    Adenauer Marinho de Oliveira Góes Junior, Salim Abdon Haber Jeha
    Case Reports in Surgery.2012; 2012: 1.     CrossRef
  • Risk factors of lymphocele after RAH with pelvic lymph node dissection for women with cervical cancer
    Ji Yen Lee, Jaeman Bae, Sun-Joo Lee, Ji Yeon Kim, Soo Nyung Kim
    Korean Journal of Obstetrics & Gynecology.2012; 55(12): 907.     CrossRef
  • Body mass index and survival in patients with epithelial ovarian cancer
    Dong Hoon Suh, Hee Seung Kim, Hyun Hoon Chung, Jae Weon Kim, Noh Hyun Park, Yong Sang Song, Soon‐Beom Kang
    Journal of Obstetrics and Gynaecology Research.2012; 38(1): 70.     CrossRef
  • Lymphocele and Ovarian Cancer: Risk Factors and Impact on Survival
    Tristan Gauthier, Catherine Uzan, Delphine Lefeuvre, Aminata Kane, Geoffroy Canlorbe, Fredéric Deschamps, Catherine Lhomme, Patricia Pautier, Philippe Morice, Sébastien Gouy
    The Oncologist.2012; 17(9): 1198.     CrossRef
  • Prévention des lymphocèles et cancers gynécologiques
    T. Gauthier, S. Gouy, C. Uzan, A. Kane, P. Morice
    Gynécologie Obstétrique & Fertilité.2011; 39(12): 698.     CrossRef
  • Robot-assisted removal of a lymphocyst causing severe neuralgic pain and adductor atrophy
    Giorgio Cazzaniga, Christer Borgfeldt, Nils-Olof Wallengren, Jan Persson
    Journal of Robotic Surgery.2011; 5(4): 299.     CrossRef
  • Nonovarian Cystic Lesions of the Pelvis
    Penelope L. Moyle, Masako Y. Kataoka, Asako Nakai, Akiko Takahata, Caroline Reinhold, Evis Sala
    RadioGraphics.2010; 30(4): 921.     CrossRef
  • Late aortic lymphocele and residual ovary syndrome after gynecological surgery
    Maria Pastore, Natalina Manci, Claudia Marchetti, Francesca Esposito, Marialetizia Iuliano, Lucia Manganaro, Pierluigi Benedetti Panici
    World Journal of Surgical Oncology.2007;[Epub]     CrossRef
  • 18,287 View
  • 154 Download
  • 75 Crossref
Close layer
Expression of Matrix Metalloproteinase-9 Correlates with Poor Prognosis in Human Malignant Fibrous Histiocytoma
Jinyoung Yoo, Ji Han Jung, Seok Jin Kang, Chang Suk Kang
Cancer Res Treat. 2004;36(6):384-388.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.384
AbstractAbstract PDFPubReaderePub
Purpose

92 kDa matrix metalloproteinase-9 (MMP-9) is believed to play an important role in degrading the matrix and basement membrane, contributing to the invasion and metastasis of malignant solid tumors. However, little is known about its involvement in a malignant fibrous histiocytoma. The aim of this study was to investigate the expression of MMP-9 and to correlate its expression with clinicopathologic parameters in human malignant fibrous histiocytomas.

Materials and Methods

Archival tumor tissues from 20 patients with a malignant fibrous histiocytoma were analyzed by immunohistochemistry for the expression of MMP-9. Clinical information was obtained through the computerized retrospective database from the tumor registry.

Results

Seventeen of 20 (85%) tumors showed a positive reaction for MMP-9. MMP-9 activity was inversely correlated with patients' survival time (p=.011). There was no significant correlation between the activated MMP-9 expression and all the other clinicopathologic variables.

Conclusion

Our data demonstrate that MMP-9 activation is likely to occur in human malignant fibrous histiocytomas. It is also noteworthy that the expression of MMP-9 may aid in predicting patients' poor prognosis.

Citations

Citations to this article as recorded by  
  • Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing
    Agnieszka Śmieszek, Klaudia Marcinkowska, Zofia Małas, Mateusz Sikora, Martyna Kępska, Beata A. Nowakowska, Marta Deperas, Marta Smyk, Carlos Rodriguez-Galindo, Anna Raciborska
    BMC Cancer.2024;[Epub]     CrossRef
  • Differential expression of mitotic regulators and tumor microenvironment influences the regional growth pattern of solid sarcoma along the cranio-caudal axis
    Sukalpa Chattopadhyay, Malay Chaklader, Ritam Chatterjee, Aditya Law, Sujata Law
    Experimental Cell Research.2016; 340(1): 91.     CrossRef
  • Expression of matrix metalloproteinase-9 and significance of a macrophage assay in eosinophilic granuloma
    Manal Mohamed Zyada
    Annals of Diagnostic Pathology.2009; 13(6): 367.     CrossRef
  • 8,577 View
  • 47 Download
  • 3 Crossref
Close layer
Photodynamic Effects of Radachlorin® on Cervical Cancer Cells
Su-Mi Bae, Yong-Wook Kim, Joon-Mo Lee, Sung-Eun Namkoong, Sei-Jun Han, Jong-Ki Kim, Chang-Hee Lee, Heung-Jae Chun, Hyun-Sun Jin, Woong-Shick Ahn
Cancer Res Treat. 2004;36(6):389-394.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.389
AbstractAbstract PDFPubReaderePub
Purpose

Photodynamic therapy (PDT) is a novel treatment modality, which produces local tissue necrosis with laser light following the prior administration of a photosensitizing agent. Radachlorin® has recently been shown to be a promising PDT sensitizer. In order to elucidate the antitumor effects of PDT using Radachlorin® on cervical cancer, growth inhibition studies on a HPV-associated tumor cell line, TC-1 cells in vitro and animals with an established TC-1 tumor in vivo were determined.

Materials and Methods

TC-1 tumor cells were exposed to various concentrations of Radachlorin® and PDT, with irradiation of 12.5 or 25 J/cm2 at an irradiance of 20 mW/cm2 using a Won-PDT D662 laser at 662 nm in vitro. C57BL/6 mice with TC-1 tumor were injected with Radachlorin® via different routes and treated with PDT in vivo. A growth suppression study was then used to evaluate the effects at various time points after PDT.

Results

The results showed that irradiation of TC-1 tumor cells in the presence of Radachlorin® induced significant cell growth inhibition. Animals with established TC-1 tumors exhibited significantly smaller tumor sizes over time when treated with Radachlorin® and irradiation.

Conclusion

PDT after the application of Radachlorin® appears to be effective against TC-1 tumors both in vitro and in vivo.

Citations

Citations to this article as recorded by  
  • Photodynamic Therapy for Thyroid Cancer
    Julia Inglot, Joanna Katarzyna Strzelczyk, Dorota Bartusik-Aebisher, David Aebisher
    BioMed.2025; 5(1): 8.     CrossRef
  • Photodynamic therapy: Innovative approaches for antibacterial and anticancer treatments
    Marketa Kolarikova, Barbora Hosikova, Hanna Dilenko, Katerina Barton‐Tomankova, Lucie Valkova, Robert Bajgar, Lukas Malina, Hana Kolarova
    Medicinal Research Reviews.2023; 43(4): 717.     CrossRef
  • Applications of Photodynamic Therapy in Endometrial Diseases
    Gabriela Correia-Barros, Beatriz Serambeque, Maria João Carvalho, Carlos Miguel Marto, Marta Pineiro, Teresa M. V. D. Pinho e Melo, Maria Filomena Botelho, Mafalda Laranjo
    Bioengineering.2022; 9(5): 226.     CrossRef
  • Photodynamic treatment with purpurin 18 effectively inhibits triple negative breast cancer by inducing cell apoptosis
    Pengyun Huang, Baoting Zhang, Qiuju Yuan, Xie Zhang, Wingnang Leung, Chuanshan Xu
    Lasers in Medical Science.2021; 36(2): 339.     CrossRef
  • Assessing of integration of ionizing radiation with Radachlorin-PDT on MCF-7 breast cancer cell treatment
    R. Ghoodarzi, V. Changizi, A. R. Montazerabadi, N. Eyvazzadaeh
    Lasers in Medical Science.2016; 31(2): 213.     CrossRef
  • Chlorophyll a Covalently Bonded to Organo-Modified Translucent Silica Xerogels: Optimizing Fluorescence and Maximum Loading
    M. García-Sánchez, I. Serratos, R. Sosa, T. Tapia-Esquivel, F. González-García, F. Rojas-González, S. Tello-Solís, A. Palacios-Enriquez, J. Esparza Schulz, A. Arrieta
    Molecules.2016; 21(7): 961.     CrossRef
  • Evaluation of Silicon Phthalocyanine 4 Photodynamic Therapy against Human Cervical Cancer Cells <i>in Vitro</i> and in Mice
    Jill A. Gadzinski, Jianxia Guo, Brian J. Philips, Per Basse, Ethan K. Craig, Lisa Bailey, Joseph Latoche, John T. Comerci, Julie L. Eiseman
    Advances in Biological Chemistry.2016; 06(06): 193.     CrossRef
  • Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors
    Jan Willem Kleinovink, Pieter B. van Driel, Thomas J. Snoeks, Natasa Prokopi, Marieke F. Fransen, Luis J. Cruz, Laura Mezzanotte, Alan Chan, Clemens W. Löwik, Ferry Ossendorp
    Clinical Cancer Research.2016; 22(6): 1459.     CrossRef
  • Development of radiolabeled radachlorin complex as a possible tumor targeting agent
    Yousef Fazaeli, Amir R. Jalilian, Fatemeh Rezaee, Tahereh Firouzyar, Sedigheh Moradkhani, Azar Bagheri, Abbas Majdabadi
    Journal of Radioanalytical and Nuclear Chemistry.2015; 303(3): 1695.     CrossRef
  • Photodynamic therapy: An adjunct to conventional root canal disinfection strategies
    Shipra Singh, Rajni Nagpal, Naveen Manuja, Sashi Prabha Tyagi
    Australian Endodontic Journal.2015; 41(2): 54.     CrossRef
  • The efficacy of Radachlorin-mediated photodynamic therapy in human hepatocellular carcinoma cells
    Hamidreza Mirzaei, Gholamreza Esmaeeli Djavid, Mahnaz Hadizadeh, Maryam Jahanshiri-Moghadam, Parastoo Hajian
    Journal of Photochemistry and Photobiology B: Biology.2015; 142: 86.     CrossRef
  • Chlorin e6 Derivative Radachlorin Mainly Accumulates in Mitochondria, Lysosome and Endoplasmic Reticulum and Shows High Affinity toward Tumors in Nude Mice in Photodynamic Therapy
    Raktim Biswas, Jeong Hwan Moon, Jin‐Chul Ahn
    Photochemistry and Photobiology.2014; 90(5): 1108.     CrossRef
  • Microscopic analysis of the localization of two chlorin‐based photosensitizers in OSC19 tumors in the mouse oral cavity
    Floor van Leeuwen–van Zaane, Pieter B.A.A. van Driel, Ute A. Gamm, Thomas J.A. Snoeks, Henriëtte S. de Bruijn, Angelique van der Ploeg–van den Heuvel, Clemens W.G.M. Löwik, Henricus J.C.M. Sterenborg, Arjen Amelink, Dominic J. Robinson
    Lasers in Surgery and Medicine.2014; 46(3): 224.     CrossRef
  • Photodynamic effect of Radachlorin on nerve and glial cells
    M.A. Neginskaya, E.V. Berezhnaya, M.V. Rudkovskii, S.V. Demyanenko, A.B. Uzdensky
    Photodiagnosis and Photodynamic Therapy.2014; 11(3): 357.     CrossRef
  • Fluorescence optimization of chlorophyll covalently bonded to mesoporous silica synthesized by the sol–gel method
    I.N. Serratos, F. Rojas-González, R. Sosa-Fonseca, J.M. Esparza-Schulz, V. Campos-Peña, S.R. Tello-Solís, M.A. García-Sánchez
    Journal of Photochemistry and Photobiology A: Chemistry.2013; 272: 28.     CrossRef
  • Efficacy and Safety of Photodynamic Therapy for Recurrent, High Grade Nonmuscle Invasive Bladder Cancer Refractory or Intolerant to Bacille Calmette-Guérin Immunotherapy
    Joo Yong Lee, Richilda Red Diaz, Kang Su Cho, Meng Shi Lim, Jae Seung Chung, Won Tae Kim, Won Sik Ham, Young Deuk Choi
    Journal of Urology.2013; 190(4): 1192.     CrossRef
  • Crossed and Linked Histories of Tetrapyrrolic Macrocycles and Their Use for Engineering Pores within Sol-Gel Matrices
    Miguel García-Sánchez, Fernando Rojas-González, E. Menchaca-Campos, Salvador Tello-Solís, R. Quiroz-Segoviano, Luis Diaz-Alejo, Eduardo Salas-Bañales, Antonio Campero
    Molecules.2013; 18(1): 588.     CrossRef
  • Photodynamic Therapy for Recurrent Head and Neck Malignancy
    Yong-Sik Lee, Young-Chang Lim, Yeo-Jin Lee, Mun-Su Park, Jae-Myeong Kim
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2011; 54(4): 271.     CrossRef
  • Evaluation of the effect of photoactivated disinfection with Radachlorin® against Streptococcus mutans (an in vitro study)
    Reza Fekrazad, Majid Bargrizan, Sepideh Sajadi, Soodabeh Sajadi
    Photodiagnosis and Photodynamic Therapy.2011; 8(3): 249.     CrossRef
  • In vitro evaluation of Radachlorin® sensitizer for photodynamic therapy
    Samuel Douillard, Isabelle Lhommeau, David Olivier, Thierry Patrice
    Journal of Photochemistry and Photobiology B: Biology.2010; 98(2): 128.     CrossRef
  • In vitro and in vivo evaluation of Radachlorin® sensitizer for photodynamic therapy
    Samuel Douillard, David Olivier, Thierry Patrice
    Photochemical & Photobiological Sciences.2009; 8(3): 405.     CrossRef
  • Role of Microarray in Cancer Diagnosis
    Hoguen Kim
    Cancer Research and Treatment.2004; 36(1): 1.     CrossRef
  • 11,987 View
  • 69 Download
  • 22 Crossref
Close layer
Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
Eun-Kyoung Yim, Jun-Sang Bae, Seung-Bak Lee, Keun-Ho Lee, Chan-Joo Kim, Sung-Eun Namkoong, Soo-Jong Um, Jong-Sup Park
Cancer Res Treat. 2004;36(6):395-399.   Published online December 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.6.395
AbstractAbstract PDFPubReaderePub
Purpose

It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there is little information regarding the antineoplastic mechanism of paclitaxel against cervical carcinoma cells. We thus tried to analyze differential protein expression and antineoplastic mechanism-related proteins after paclitaxel treatment on cervical cancer cells by using a proteomic analysis and to investigate the mechanism of action.

Materials and Methods

Using proteomics analysis including 2-DE and MALDI-TOF-MS, we detected the antineoplastic mechanism-related proteins. Then, we performed western blot analysis for apoptosis- and transformation-related proteins to confirm expression patterns derived from proteome analysis after paclitaxel treatment.

Results

We identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells using proteomics methods. Paclitaxel treatment elevated mainly apoptosis, immune response and cell cycle check point-related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Also, in the HPV-associated cervical carcinoma cells, paclitaxel demonstrated anti-proliferative activity through the membrane death receptor-mediated apoptotic pathway and the mitochondrial-mediated pathway.

Conclusion

Identification and characterization of functionally modulated proteins involved in anti-cancer regulatory events should lead to a better understanding of the long-term actions of paclitaxel at the molecular level and will contribute to the future development of novel therapeutic drug treatments based upon current therapies.

Citations

Citations to this article as recorded by  
  • Proteomic Analysis of Thermus thermophilus Cells after Treatment with Antimicrobial Peptide
    Alexey K. Surin, Anna I. Malykhina, Michail V. Slizen, Alexey P. Kochetov, Mariya Yu. Suvorina, Vadim E. Biryulyov, Sergei Y. Grishin, Oxana V. Galzitskaya
    Bacteria.2024; 3(4): 299.     CrossRef
  • Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring
    Georgia Kontostathi, Jerome Zoidakis, Nicholas P. Anagnou, Kalliopi I. Pappa, Antonia Vlahou, Manousos Makridakis
    Expert Review of Proteomics.2016; 13(8): 731.     CrossRef
  • PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer
    Haiyan Zhu, Jun Wu, Wenwen Zhang, Hui Luo, Zhaojun Shen, Huihui Cheng, Xueqiong Zhu
    Scientific Reports.2016;[Epub]     CrossRef
  • Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria
    Yang Wang, Ru-Yuan Yu, Qing-Yu He
    Evidence-Based Complementary and Alternative Medicine.2015; 2015: 1.     CrossRef
  • Mass Spectrometry-Based Proteomics in Molecular Diagnostics: Discovery of Cancer Biomarkers Using Tissue Culture
    Debasish Paul, Avinash Kumar, Akshada Gajbhiye, Manas K. Santra, Rapole Srikanth
    BioMed Research International.2013; 2013: 1.     CrossRef
  • Identification of Cervical Cancer Proteins Associated With Treatment With Paclitaxel and Cisplatin in Patients
    Huiling Liu, Yin Han, Ruoran Mi, Ying Zhang, Gang Su, Hailin Wang, Xin Zhou, Xiangwen Liu, Bingdong Zhu
    International Journal of Gynecological Cancer.2011; 21(8): 1452.     CrossRef
  • Impact of taxol on dermal papilla cells — A proteomics and bioinformatics analysis
    Pei-Hsiu Chen, Chih-Yuan Wang, Ching-Wu Hsia, Ming-Yi Ho, Ann Chen, Min-Jen Tseng, Yung-Fu Wu, Han-Min Chen, Tzu-Hao Huang, Hung-Te Liu, Hao-Ai Shui
    Journal of Proteomics.2011; 74(12): 2760.     CrossRef
  • 10,818 View
  • 64 Download
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP